Explore

Trendline Trendline
Telix Pharmaceuticals Launches $550 Million Convertible Bonds Offering

Telix Pharmaceuticals Launches $550 Million Convertible Bonds Offering

Telix Pharmaceuticals Launches $550 Million Convertible Bonds Offering
Trendline Trendline
Telix Pharmaceuticals Launches $550 Million Convertible Bonds Offering to Refinance Existing Debt

Telix Pharmaceuticals Launches $550 Million Convertible Bonds Offering to Refinance Existing Debt

Telix Pharmaceuticals Launches $550 Million Convertible Bonds Offering to Refinance Existing Debt
Trendline Trendline
Regeneron Partners with Telix in $4.3 Billion Radiopharmaceutical Alliance

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceutical Alliance

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceutical Alliance
Trendline Trendline
Regeneron and Telix Partner in $4.3 Billion Radiopharmaceutical Collaboration

Regeneron and Telix Partner in $4.3 Billion Radiopharmaceutical Collaboration

Regeneron and Telix Partner in $4.3 Billion Radiopharmaceutical Collaboration
Trendline Trendline
Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream
Trendline Trendline
Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent
Trendline Trendline
Almirall and Barcelona Supercomputing Center Enhance Collaboration in Dermatology Innovation

Almirall and Barcelona Supercomputing Center Enhance Collaboration in Dermatology Innovation

Almirall and Barcelona Supercomputing Center Enhance Collaboration in Dermatology Innovation
Trendline Trendline
Patient-Centric Approach in Drug Development Seen as Competitive Advantage

Patient-Centric Approach in Drug Development Seen as Competitive Advantage

Patient-Centric Approach in Drug Development Seen as Competitive Advantage
Trendline Trendline
Frontier Medicines Appoints David R. Epstein to Board of Directors to Drive Growth

Frontier Medicines Appoints David R. Epstein to Board of Directors to Drive Growth

Frontier Medicines Appoints David R. Epstein to Board of Directors to Drive Growth
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Regeneron Partners with Telix in $4.3 Billion Radiopharmaceuticals Deal Targeting Cancer

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceuticals Deal Targeting Cancer

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceuticals Deal Targeting Cancer
Trendline Trendline
Citi Expands Data Center Financing to Compete with Wall Street Rivals

Citi Expands Data Center Financing to Compete with Wall Street Rivals

Citi Expands Data Center Financing to Compete with Wall Street Rivals